EYLEA® Proposed Biosimilar M710 BPCIA Appeals Dismissed

On April 12, 2024, the Federal Circuit dismissed CAFC Appeal No. 24-1402 and Cross-Appeal No. 24-1405 for lack of jurisdiction following its February 22, 2024 order directing Regeneron and Mylan / Biocon.

Related Keywords

Formycon Klinge Biopharma , Mylan Biocon , April Breyer Menon , Biocon , District Court , Federal Circuit , Klinge Biopharma , Samsung Bioepis , Mondaq , Eylea Xae Proposed Biosimilar M710 Bpcia Appeals Dismissed For Lack Of Jurisdiction , Food , Drugs , Healthcare , Life Sciences , Iotechnology Amp Nanotechnology , Intellectual Property , Patent , Litigation , Ediation Amp Arbitration , Trials Amp Appeals Compensation , ,